an update on allohsct in scd
Published 2 years ago • 46 plays • Length 3:12Download video MP4
Download video MP3
Similar videos
-
0:45
current landscape of treatment for scd: an update from ash 2023
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:23
current status of allohsct in bp-mpns
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:12
an update in cellular therapies: gene editing for scd and immunotherapies for mm
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:41
israeli company on the edge of finding diabetes cure
-
8:57
outcomes of sct in t-all and t-lbl
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:16
gbt021601, a next generation hbs polymerization inhibitor for the treatment of scd
-
0:54
a research update in richter's transformation from ash 2023
-
1:43
approval of exa-cel for scd
-
1:03
late effect surveillance following allosct: the publication of new guidelines
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:32
factors contributing to the pathogenesis of icaht
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
0:42
the limited access to novel therapeutics for sickle cell disease in lmics
-
2:58
long-term updates from the reach trial of hydroxyurea in pediatric patients with scd in ssa
-
2:31
selinexor in the myeloma treatment landscape and managing associated side effects
-
2:20
ebmt diagnostic criteria for tma post-allosct and the role of complement activation